Salazar, Ruth
The University of Texas MD Anderson Cancer Center
3 papers on CoChatORCID 0000-0001-7496-7765
Most cited papers
- Verified
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology
Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 1,452
- Verified
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Keung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment
Cited by 215
- Verified
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah, N., Conley, A. P., Parra, E. R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., et al. (2022) · The Lancet Oncology
Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 159
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free